Aptamer Group Signs Therapeutic Development Agreement with Invizius to Advance Complement System Treatments

Aptamer Group links up with Invizius to sharpen complement system therapies

Aptamer Group (AIM: APTA) has signed a therapeutic development agreement with Invizius, a clinical-stage biotech focused on second-generation complement system therapies. The aim: develop Optimer binders that target key components of the complement system and slot into Invizius’ H-Guard therapy platform.

The financial terms are not disclosed, but the strategic intent is crystal clear. Aptamer keeps the intellectual property on any binders it develops, preserving future licensing and commercialisation options. In plain English: if these binders work and get used in therapies, Aptamer could see royalty-type upside down the line.

What the deal actually covers

Under the agreement, Aptamer will create Optimer binders to “critical factors” of the complement system. The complement system is part of the immune response; when it goes off-target, it can drive inflammatory, fibrotic, and autoimmune diseases. Current drugs can dampen this system, but often in a broad-brush way that risks side effects.

Invizius’ H-Guard platform, which is entering Phase 2 clinical trials, currently uses protein-based molecules to modulate the complement system. Swapping in Optimers could make H-Guard more precise, safer, and less likely to trigger immune reactions, according to the RNS.

One early focus named is IgA nephropathy, a serious kidney disease with limited treatment options. More precise complement modulation here would be a meaningful clinical advance if it delivers.

Quick primer: Optimers and the complement system

Optimers are synthetic oligonucleotide-based binders. Think of them as engineered molecules that latch onto specific biological targets, similar to antibodies, but with some useful twists.

• Enhanced specificity – designed to bind only the intended target.
• Biological stability – robust performance in real-world conditions.
• Reduced immunogenicity – less likely to provoke an unwanted immune response.

These traits are exactly what you want when fine-tuning the complement system, where over-suppression risks infections and under-suppression risks disease flare.

Why this matters: market size and Aptamer’s model

The complement-targeting therapy market was valued at US$7.1 billion in 2024, per the RNS. That is already a sizeable pot, and improved targeting should have room to win share if safety and efficacy stack up.

Aptamer runs a fee-for-service business in the US$210 billion market for antibody alternatives and says it works with all top 10 global pharma companies. Crucially for investors, the company is pushing a licensing-led growth model: build valuable Optimer assets with partners and earn licensing and royalty streams over time. Keeping IP in this Invizius deal aligns neatly with that approach.

Item	Detail
Parties	Aptamer Group and Invizius
Therapeutic area	Complement system modulation
Platform	Invizius H-Guard (entering Phase 2)
Aptamer deliverable	Optimer binders to critical complement factors
Target indications	Multiple, including IgA nephropathy
Financial terms	Not disclosed
IP ownership	Aptamer retains IP on developed binders
Market size	US$7.1 billion (complement therapies, 2024)

Strategic fit: licensing potential front and centre

Aptamer’s CEO calls this a “strong strategic fit” with a licensing-led model and highlights recent “recurring revenue potential” demonstrated with top-tier pharma partners. The subtext: Optimer assets that integrate into third-party therapies can be monetised via licences and royalties, which tend to be higher-margin and more predictable once established.

Retaining IP is therefore a notable plus. It strengthens Aptamer’s proprietary portfolio and keeps the door open for future deals, potentially both with Invizius and others targeting the complement pathway.

What could Optimers change for H-Guard?

H-Guard currently uses protein-based molecules. The RNS suggests Optimers could make it safer and more precise, with lower risk of side effects. If borne out in development, that could improve the benefit-risk profile across multiple indications where complement plays a role.

It is worth stressing: this is development-stage work. Neither efficacy nor safety improvements are guaranteed until they are shown in application-relevant testing and, ideally, in clinical settings. But the rationale is sound, given the inherent advantages Aptamer outlines for the Optimer modality.

Positives for investors

• Clear market opportunity in a US$7.1 billion segment with unmet need.
• IP retention creates optionality for licensing and royalty income.
• Partnership with a clinical-stage company whose platform is entering Phase 2, suggesting momentum.
• Optimer characteristics (specificity, stability, low immunogenicity) well matched to complement modulation.
• Reinforces Aptamer’s push beyond fee-for-service towards asset-backed revenues.

What’s not disclosed – and risks to keep in mind

• Financial terms: not disclosed, so near-term revenue impact cannot be assessed.
• Timelines and milestones: not disclosed; investors lack visibility on when to expect data or licence triggers.
• Technical risk: substituting protein-based agents with aptamers must prove out in the H-Guard context.
• Clinical and regulatory risk sits with the ultimate therapy; success is not guaranteed.

What to watch next

Look for updates on Optimer discovery and validation against the intended complement targets, and any indication that these binders are being integrated into H-Guard programmes. Any future statements on licensing structures, royalties, or milestone payments would be particularly informative for the investment case.

Given Aptamer’s comments about expanding its footprint in high-value therapeutic markets, keep an eye out for additional partnerships that similarly preserve IP and hint at scalable licensing revenues.

Bottom line: a strategically tidy deal with optionality

This agreement ticks the right boxes for Aptamer: it targets a meaningful market, leverages the supposed strengths of Optimers, and – crucially – keeps the IP in-house. While we lack financial detail and timelines, the direction of travel towards licensing and royalty-bearing assets is positive.

Execution will matter: delivering high-performance binders under application-relevant conditions, then seeing them adopted in clinical programmes. If Aptamer and Invizius can demonstrate a safer, more precise complement therapy approach, the commercial prize could be material.

Company background and investor resources

Aptamer Group develops Optimer binders for use across medicine, diagnostics, and research tools, highlighting stability, reliable performance, and lower costs versus traditional antibodies. The company listed on AIM in December 2021 and is headquartered in York, UK.

To receive company updates, investors can register for email alerts on Aptamer’s website: Aptamer Group investor news alerts.